Bush et al., 1992 - Google Patents
An abnormality of plasma amyloid protein precursor in Alzheimer's diseaseBush et al., 1992
- Document ID
- 11057250048414936164
- Author
- Bush A
- Whyte S
- Thomas L
- Williamson T
- Van Tiggelen C
- Currie J
- Small D
- Moir R
- Li Q
- Rumble B
- Mönning U
- Beyreuther K
- Masters C
- Publication year
- Publication venue
- Annals of neurology
External Links
Snippet
Abstract βA4 amyloid deposition in the brain, which is characteristic of Alzheimer's disease (AD), may result from either overexpression of the amyloid protein precursor (APP) or failure of APP to be correctly processed. A blood marker reflecting this abnormal metabolism would …
- 102000014303 Amyloid beta-Protein Precursor 0 title abstract description 153
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/573—Immunoassay; Biospecific binding assay for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—G01N2333/4701
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bush et al. | An abnormality of plasma amyloid protein precursor in Alzheimer's disease | |
| US5270165A (en) | Method of diagnosis of amyloidoses | |
| Kennard et al. | Serum levels of the iron binding protein p97 are elevated in Alzheimer′ s disease | |
| EP0847530B1 (en) | QUANTITATION OF p97 TO DIAGNOSE AND MONITOR ALZHEIMER'S DISEASE | |
| US7442516B2 (en) | Antibody specific to central nervous system tau protein | |
| AU669493B2 (en) | A method for assaying and treating Alzheimer's disease | |
| El‐Agnaf et al. | Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease | |
| US5601985A (en) | Method of detecting abnormally phosphorylated tau(τ) | |
| US7387879B2 (en) | Diagnosis of tauopathies | |
| Pirttila et al. | α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease | |
| US9733260B2 (en) | Biochemical markers for neurodegenerative conditions | |
| US6495335B2 (en) | Compositions and methods for diagnosing alzheimer's disease | |
| EP0540591B1 (en) | Cell necrosis detection through assays for spectrin and breakdown products thereof | |
| Lieberman et al. | Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia | |
| JP2005528588A (en) | Detection and / or monitoring of synuclein-related diseases | |
| WO1992000521A1 (en) | Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor | |
| WO2008031190A1 (en) | Alpha-1-antitrypsin as a diagnostic/prognostic indicator for neurodegenerative diseases | |
| AU701954B2 (en) | A method for assaying and treating Alzheimer's disease | |
| Mehta | Amyloid beta and tau proteins in Alzheimer’s disease and Down syndrome | |
| Mehta | Amyloid beta and tau proteins in | |
| Amberla et al. | 669 Tau levels in CSF are related to cognitive functions in familial Alzheimer's disease | |
| MXPA98001641A (en) | Quantification of p97 to diagnose and monitor alzhei's disease |